BOT 16.9% 38.0¢ botanix pharmaceuticals ltd

BOT - Anything but charting, page-5306

  1. 482 Posts.
    lightbulb Created with Sketch. 609
    Always appreciate your contributions Marsman but with so many more shares in the market, the comparison in terms of value between now and prior to Phase 2 acne is probably better based upon market cap. Still a little ways to go for the current market to equate to previous highs but at roughly 240million we are getting fairly close, not sure if anyone can recall exactly but I thought BOT hit around 270 or 280.

    I think Clinuvel might be a good comparison. ASX listed, single product for photosensitivity, a relatively rare skin condition with a few other irons in the research phase. Present market cap is just under 900million on revenue of 66million.


 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.